Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.

ABSTRACT:

Purpose

Hypertension is a mechanism-based toxicity of sorafenib and other cancer therapeutics that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. This prospective, single-center, cohort study characterized ambulatory blood pressure monitoring as an early pharmacodynamic biomarker of VEGF signaling pathway inhibition by sorafenib.

Experimental design

Fifty-four normotensive advanced cancer patients underwent 24-hour ambulatory blood pressure monitoring before and between days 6 and 10 of sorafenib therapy. After blood pressure changes were detected among the first cohort within 10 days, ambulatory blood pressure monitoring was done during the first 24 hours of treatment for the second cohort.

Results

For the entire patient population, the bloo

SUBMITTER: Maitland ML 

PROVIDER: S-EPMC2756980 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature